CMV Antiviral Resistance Sequencing
Test Code: 5600
Cpt Code:87910 (x1)
CMV infections are a major cause of morbidity and mortality among immunocompromised patients. Patient outcomes depend on rapid diagnosis and treatment with antiviral therapies, including ganciclovir, valganciclovir, foscarnet, and cidofovir. Unfortunately, the risk of developing an antiviral-resistant strain of CMV with continued antiviral use in either prophylaxis or preemptive therapy regimens is rising. Proper patient management requires rapid detection of resistance and immediate therapy modification. Laboratory testing should be used to confirm the occurrence of antiviral resistance, as treatment modification based solely on clinical suspicion may result in added toxicity and increased complexity in patient management. The use of gene sequencing offers distinct advantages over other methods, including a rapid turnaround time, a broader range of antiviral resistance information, and the ability to provide information concerning new drugs as they become available.
Conventional PCR followed by gene sequencing. Sequencing analysis provides information on selected locations in two genes involved in CMV antiviral resistance: UL97 and UL54. Mutations in the UL97 phosphotransferase gene have been implicated in ganciclovir resistance. Mutations in the UL54 DNA polymerase gene may confer ganciclovir, foscarnet, and cidofovir resistance. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Mutations in the UL97 and UL54 genes will be reported as Resistant/None Detected. Interpretation of gene mutations and association with antiviral resistance, including ganciclovir, foscarnet, and cidofovir, will be provided with the report. See CMV AVR Reportable Mutations in the test information navigation (right side of webpage).
Causes For Rejection
CMV DNA concentrations too low to allow antiviral resistance testing, whole blood frozen, specimens beyond their acceptable length of time from collection as listed in the specimen handling, or specimen types other than those listed.
2-4 days (Monday through Saturday).
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor-IBT test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor-IBT Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086
NY approved.Collect 4-5 mL whole blood in EDTA or ACD tube, centrifuge and transfer 2 mL plasma to sterile, screw top tube. Can be shipped at ambient or frozen temperature Monday through Friday. Specimens shipped at ambient temperature must be received within 96 hrs of collection.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor-IBT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor-IBT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.